Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy
Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in pa...
Gespeichert in:
| Veröffentlicht in: | Klinická onkologie 2016, Vol.29 (2), p.127-132 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | cze ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 132 |
|---|---|
| container_issue | 2 |
| container_start_page | 127 |
| container_title | Klinická onkologie |
| container_volume | 29 |
| creator | Richter, I Dvořák, J Hejzlarová, V Chalupa, J Sochor, M Stankuš, I Barsová, L Holikova, M Forster, J Bartoš, J |
| description | Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC.
A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival.
The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295- 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934- 3.308; p = 0.939) between enzalutamide and abirateron.
Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy. |
| doi_str_mv | 10.14735/amko2016127 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1782215720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1782215720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1747-46f327a3f1c9c382e5c0c0237ff4a4d1c7c032bd141b715324b178479f39f59c3</originalsourceid><addsrcrecordid>eNpNkLtPwzAQxi0EolXpxow8MhDwM07GKioPqQiGIrFFjnNWA3kU2xnKX4-hBXHLne773afTh9A5JddUKC5vdPc-MEJTytQRmtKMsERyoo7RlGQpS0QuXydo7v0biZUyJWV2iiZMkSyyfIr8sv_U7Rh019SAdV_jRdU4HcANPeCmx2EDeO1Ahw76gAeLHyFoH3RoDC7iENlm6BMHvonbiDy74VuGqPYGHNY2muFiA90QvZze7s7QidWth_mhz9DL7XJd3Cerp7uHYrFKDFVCJSK1nCnNLTW54RkDaYghjCtrhRY1NcoQzqqaClopKjkTFVWZULnluZXxZIYu975bN3yM4EPZNd5A2-oehtGXkWaMSsVIRK_2qInfewe23Lqm025XUlL-JF3-SzriFwfnseqg_oN_c-VfQjp6aw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1782215720</pqid></control><display><type>article</type><title>Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Richter, I ; Dvořák, J ; Hejzlarová, V ; Chalupa, J ; Sochor, M ; Stankuš, I ; Barsová, L ; Holikova, M ; Forster, J ; Bartoš, J</creator><creatorcontrib>Richter, I ; Dvořák, J ; Hejzlarová, V ; Chalupa, J ; Sochor, M ; Stankuš, I ; Barsová, L ; Holikova, M ; Forster, J ; Bartoš, J</creatorcontrib><description>Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC.
A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival.
The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295- 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934- 3.308; p = 0.939) between enzalutamide and abirateron.
Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy.</description><identifier>ISSN: 0862-495X</identifier><identifier>EISSN: 1802-5307</identifier><identifier>DOI: 10.14735/amko2016127</identifier><identifier>PMID: 27081803</identifier><language>cze ; eng</language><publisher>Czech Republic</publisher><subject>Aged ; Aged, 80 and over ; Androstenes - therapeutic use ; Antineoplastic Agents - therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Phenylthiohydantoin - analogs & derivatives ; Phenylthiohydantoin - therapeutic use ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Prostatic Neoplasms, Castration-Resistant - mortality ; Prostatic Neoplasms, Castration-Resistant - pathology ; Retrospective Studies</subject><ispartof>Klinická onkologie, 2016, Vol.29 (2), p.127-132</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1747-46f327a3f1c9c382e5c0c0237ff4a4d1c7c032bd141b715324b178479f39f59c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4023,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27081803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Richter, I</creatorcontrib><creatorcontrib>Dvořák, J</creatorcontrib><creatorcontrib>Hejzlarová, V</creatorcontrib><creatorcontrib>Chalupa, J</creatorcontrib><creatorcontrib>Sochor, M</creatorcontrib><creatorcontrib>Stankuš, I</creatorcontrib><creatorcontrib>Barsová, L</creatorcontrib><creatorcontrib>Holikova, M</creatorcontrib><creatorcontrib>Forster, J</creatorcontrib><creatorcontrib>Bartoš, J</creatorcontrib><title>Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy</title><title>Klinická onkologie</title><addtitle>Klin Onkol</addtitle><description>Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC.
A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival.
The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295- 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934- 3.308; p = 0.939) between enzalutamide and abirateron.
Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androstenes - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Phenylthiohydantoin - analogs & derivatives</subject><subject>Phenylthiohydantoin - therapeutic use</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Prostatic Neoplasms, Castration-Resistant - mortality</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Retrospective Studies</subject><issn>0862-495X</issn><issn>1802-5307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkLtPwzAQxi0EolXpxow8MhDwM07GKioPqQiGIrFFjnNWA3kU2xnKX4-hBXHLne773afTh9A5JddUKC5vdPc-MEJTytQRmtKMsERyoo7RlGQpS0QuXydo7v0biZUyJWV2iiZMkSyyfIr8sv_U7Rh019SAdV_jRdU4HcANPeCmx2EDeO1Ahw76gAeLHyFoH3RoDC7iENlm6BMHvonbiDy74VuGqPYGHNY2muFiA90QvZze7s7QidWth_mhz9DL7XJd3Cerp7uHYrFKDFVCJSK1nCnNLTW54RkDaYghjCtrhRY1NcoQzqqaClopKjkTFVWZULnluZXxZIYu975bN3yM4EPZNd5A2-oehtGXkWaMSsVIRK_2qInfewe23Lqm025XUlL-JF3-SzriFwfnseqg_oN_c-VfQjp6aw</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Richter, I</creator><creator>Dvořák, J</creator><creator>Hejzlarová, V</creator><creator>Chalupa, J</creator><creator>Sochor, M</creator><creator>Stankuš, I</creator><creator>Barsová, L</creator><creator>Holikova, M</creator><creator>Forster, J</creator><creator>Bartoš, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2016</creationdate><title>Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy</title><author>Richter, I ; Dvořák, J ; Hejzlarová, V ; Chalupa, J ; Sochor, M ; Stankuš, I ; Barsová, L ; Holikova, M ; Forster, J ; Bartoš, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1747-46f327a3f1c9c382e5c0c0237ff4a4d1c7c032bd141b715324b178479f39f59c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>cze ; eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androstenes - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Phenylthiohydantoin - analogs & derivatives</topic><topic>Phenylthiohydantoin - therapeutic use</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Prostatic Neoplasms, Castration-Resistant - mortality</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Richter, I</creatorcontrib><creatorcontrib>Dvořák, J</creatorcontrib><creatorcontrib>Hejzlarová, V</creatorcontrib><creatorcontrib>Chalupa, J</creatorcontrib><creatorcontrib>Sochor, M</creatorcontrib><creatorcontrib>Stankuš, I</creatorcontrib><creatorcontrib>Barsová, L</creatorcontrib><creatorcontrib>Holikova, M</creatorcontrib><creatorcontrib>Forster, J</creatorcontrib><creatorcontrib>Bartoš, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Klinická onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Richter, I</au><au>Dvořák, J</au><au>Hejzlarová, V</au><au>Chalupa, J</au><au>Sochor, M</au><au>Stankuš, I</au><au>Barsová, L</au><au>Holikova, M</au><au>Forster, J</au><au>Bartoš, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy</atitle><jtitle>Klinická onkologie</jtitle><addtitle>Klin Onkol</addtitle><date>2016</date><risdate>2016</risdate><volume>29</volume><issue>2</issue><spage>127</spage><epage>132</epage><pages>127-132</pages><issn>0862-495X</issn><eissn>1802-5307</eissn><abstract>Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC.
A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival.
The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295- 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934- 3.308; p = 0.939) between enzalutamide and abirateron.
Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy.</abstract><cop>Czech Republic</cop><pmid>27081803</pmid><doi>10.14735/amko2016127</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0862-495X |
| ispartof | Klinická onkologie, 2016, Vol.29 (2), p.127-132 |
| issn | 0862-495X 1802-5307 |
| language | cze ; eng |
| recordid | cdi_proquest_miscellaneous_1782215720 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Androstenes - therapeutic use Antineoplastic Agents - therapeutic use Humans Male Middle Aged Neoplasm Metastasis Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Prostatic Neoplasms, Castration-Resistant - pathology Retrospective Studies |
| title | Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A13%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enzalutamide%20and%20Abiraterone%20in%20the%20Treatment%20of%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20after%20Chemotherapy&rft.jtitle=Klinick%C3%A1%20onkologie&rft.au=Richter,%20I&rft.date=2016&rft.volume=29&rft.issue=2&rft.spage=127&rft.epage=132&rft.pages=127-132&rft.issn=0862-495X&rft.eissn=1802-5307&rft_id=info:doi/10.14735/amko2016127&rft_dat=%3Cproquest_cross%3E1782215720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1782215720&rft_id=info:pmid/27081803&rfr_iscdi=true |